

References

R-15

1. ACR-SIR practice parameter for radioembolization with microsphere brachytherapy device (RMBD) for treatment of liver malignancies. Revised 2014 (Resolution 17).
2. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. American Association for Study of Liver Disease (AASLD) Practice Guideline. *Hepatology*. 2011;53(3):1020-1022.
3. Cheng AL, Kang YK, Chen Z. et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomized, double-blind, placebo-controlled trial. *Lancet Oncol*. 2009;10(1):25-34.
4. Chua TC, Bester L, Saxena A et al. Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases. *J Cancer Res Clin Oncol*. 2011;137(5):865-873.
5. ClinicalTrials.gov Searched for Radioembolization on July 28, 2017.
6. Coldwell D, Sangro B, Salem R, et al. Radioembolization in the treatment of unresectable liver tumors: experience across a range of primary cancers. *Am J Clin Oncol*. 2012;35(2):167-77.
7. Deleporte A, Flamen P, Hendlisz A. State of the art: radiolabeled microspheres treatment for liver malignancies. *Expert Opin Pharmacother*. 2010;11(4):579-86.
8. Gray B, Van Hazel G, Hope M, et al. Randomized trial of SIR-Spheres® plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. *Ann Oncol*. 2001;12(12):1711- 1720.
9. Hendlisz A, Van den Eynde M, Peeters M, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with Yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. *J Clin Oncol*. 2010; 28(23):3687-3694.
10. Kennedy AS, Dezam WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. *Am J Clin Oncol*. 2008;31(3):271- 279.
11. Kennedy A, Nag S., Salem R. et al. Recommendations for radioembolization of hepatic malignancies using Yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. *Int J Radiat Oncol Biol Phys*. 2007;68(1):13-23.
12. King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. *Cancer*. 2008;113(5):921-929.
13. Kouri BE, Abrams RA, Al-Refaie WB, et al. ACR Appropriateness Criteria® radiologic management of hepatic malignancy. Date of origin 2007. Last review date 2015.
14. Kulik LM, Atassi B, van Holsbeeck L, et al. Yttrium-90 microspheres (TheraSphere®) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. *J Surg Oncol*. 2006;94(7):572-586.
15. Kulick LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. *Hepatology*. 2008;47(1):71-81.

16. Lam MGEH, Abdelmaksoud MH, Chang DT, et al. Safety of 90Y radioembolization in patients who have undergone previous external beam radiation therapy. *Int J Radiat Oncol Biol Phys.* 2013;87(2):323-329.
17. Lau WY, Kennedy AS, Kim YH, et al. Patient selection and activity planning guide for selective internal radiotherapy with Yttrium-90 resin microspheres. *Int. J Radiat Oncol Biol Phys.* 2012;82(1):401-407.
18. Lau WY, Lai ECH, Leung TWT. Current role of selective internal irradiation with Yttrium-90 microspheres in the management of hepatocellular carcinoma: a systematic review. *Int. J. Radiat Oncol Biol Phys.* 2011;81(2):460-467.
19. Lewandowski RJ, Kulik, LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. *Am J Transplant.* 2009;9(8):1920–1928.
20. Llovet JM , Di Bisceglie AM, Bruix J. et al., Design and endpoints of clinical trials in hepatocellular carcinoma. *J Natl Cancer Inst.* 2008;100(10):698-711.
21. Llovet JM, Ricci S, Mazzaferro V, et al., Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med.* 2008;359(4):378-390.
22. Mazzaferro V, Regalia, E, Doci R , et al., Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Engl J Med.* 1996;334(11):693-700.
23. National Comprehensive Cancer Network (NCCN) Guidelines Version 1. 2018 – February 14, 2018. Hepatobiliary Cancers.
24. Nichols EM, Grabowski S, Hanlon A et al. Performance status (PS), number of lesions and interval from metastatic diagnosis treatment (IMDTT) predict for overall survival (OS) in patients treated with hepatic transarterial radioembolization (TARE) with Yttrium-90 (Y90) microspheres. *Int J Radiat Oncol Biol Phys.* 2011;81(2 Suppl):S346–S347.
25. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. *Gastroenterology.* 2010;138(1):52-64.
26. Salem R., Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodological considerations. *J Vasc Interv Radiol.* 2006; 7(8):1251-1278.
27. Salem R., Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 2: special topics. *J Vasc Interv Radiol.* 2006;17(9):1425-1439.
28. Sangro B, Bilbao JI, Boan J, et al., Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys.* 2006;66(3):792-800.
29. Saxena A, Bester L, Shan L, et al. A systematic review on the safety and efficacy of Yttrium-90 radioembolization for unresectable, chemorefractory colorectal cancer liver metastases. *J Cancer Res Clin Oncol.* 2014;140(4):537-547.
30. Schwarz RE, Abou-Alfa GK, Ghassan K., et al., Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement. *HPB (Oxford)* 2010;12(5):313–320.
31. SIR-Spheres® Microspheres Bibliography: September 2013.

32. SIR-Spheres® microspheres (Yttrium-90 Microspheres). Package insert. Sirtex Medical Inc. Wilmington MA. U.S. Food and Drug Administration (FDA). Updated January 23, 2003.
33. TheraSphere® Yttrium-90 Glass Microspheres). Package insert. BTG International Group. U.S. Food and Drug Administration (FDA). Humanitarian Device Exemptions. Updated January 4, 2000
34. Tsai AL, Burke CT, Kennedy AS, et al. Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis. *J Vasc Interv Radiol*. 2010;21(9):1377-1384.
35. U. S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH). Medical Device Reporting. Searched SIR-Spheres® MAUDE in All of FDA on July 28, 2017.
36. U. S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH). Medical Device Reporting. Searched TheraSphere® MAUDE in All of FDA on July 28, 2017.
37. U.S. Food and Drug Administration (FDA). Summary and Effectiveness Data, Radioactive Implant (Yttrium-90 microspheres). SIR-Spheres® Issued March 5, 2002.
38. U.S. Food and Drug Administration (FDA). Summary of Safety and Probably Benefit, Yttrium-90 Glass Microsphere, TheraSphere® Issued December 10, 1999.
39. Van Hazel GA, Blackwell A, Anderson J, et al. Randomized phase 2 trial of SIR-Spheres® plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. *J Surg Oncol*. 2004;88(2):78-85.
40. Van Hazel GA, Heinemann V, Sharma NK, et al. SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. *J Clin Oncol*. 2016;34(15):1723-1731.